샤르코-마리-투스병의 새로운 진단 및 치료 전략

키워드

참고문헌 (70)

1. H. Skre, "Genetic and clinical aspects of Charcot Marie Tooth’s disease", Clin Genet, 6, pp.98~118 (1974)
2. Charcot J, "Sue une forme particulaire d’atrophie musculaire progressive souvent familial debutant par les pieds et les jamber et atteingnant plus tard les mains", Rev Med, 6, pp.97~138 (1886)
3. Tooth H, "The peroneal type of progressive muscular atrophy" (1886), Lewis
4. Choi BO, "Exome sequencing is an efficient tool for genetic screening of Charcot-Marie-Tooth Disease", Hum Mutat, 33, pp.1610~1615 (2012)
5. Sereda MW, "Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT- 1A)", Nat Med, 9, pp.1533~1537 (2003)
6. Passage E, "Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease", Nat Med, 10, pp.396~401 (2004)
7. Sahenk Z, "NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients", Neurology, 65, pp.681~689 (2005)
8. Ainsworth C, "Networking for new drugs", Nat Med, 17, pp.1166~1168 (2011)[DOI]
9. Roa BB, "Déjérine-Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (PMP22) gene", Nat Genet, 5, pp.269~273 (1993)
10. Vallat JM, "Ultrastructural PMP22 expression in inherited demyelinating neuropathies", Ann Neurol, 39, pp.813~817 (1996)
11. Sereda M, "A transgenic rat model of Charcot-Marie-Tooth disease", Neuron, 16, pp.1049~1060 (1996)
12. Lemke G, "Isolation and sequence of a cDNA encoding the major structural protein of peripheral myelin", Cell, 40, pp.501~508 (1985)
13. Xu W, "Absence of PO leads to the dysregulation of myelin gene expression and myelin morphogenesis", J Neurosci Res, 60, pp.714~724 (2000)
14. Warner LE, "Clinical phenotypes of different MPZ (PO) mutations may include Charcot- Marie-Tooth type IB, Déjérine-Sottas, and congenital hypomyelination", Neuron, 17, pp.451~460 (1996)
15. Marrosu MG, "Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene", Neurology, 50, pp.1397~1401 (1998)
16. Hattori N, "Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients", Brain, 126, pp.134~151 (2003)
17. Street VA, "Mutation of a putative protein degradation gene LITAF", SIMPLE in Charcot-Marie-Tooth disease 1C, 2003, pp.60, 22~26
18. Warner LE, "Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies", Nat Genet, 18, pp.382~384 (1998)
19. Topilko P, "Krox-20 controls myelination in the peripheral nervous system", Nature, 371, pp.796~799 (1994)
20. Nagarajan R, "EGR2 mutations in inherited neuropathies dominant- negatively inhibit myelin gene expression", Neuron, 30, pp.355~368 (2001)
21. Honda S, "Mutational analysis of action of mitochondrial fusion factor mitofusin-2", J Cell Sci, 118, pp.3153~3161 (2005)
22. Züchner S, "Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot- Marie-Tooth neuropathy type 2A", Nat Genet, 36, pp.449~451 (2004)
23. Reilly MM, "Axonal Charcot-Marie-Tooth disease: The fog is slowly lifting!", Neurology, 65, pp.186~187 (2004)
24. Zhao C, "Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta", Cell, 105, pp.587~597 (2001)
25. Santel A, "Control of mitochondrial morphology by a human mitofusin", J Cell Sci, 114, pp.867~874 (2001)
26. Chen H, "Disruption of fusion results in mitochondrial heterogeneity and dysfunction", J Biol Chem, 280, pp.26185~26192 (2005)
27. Eura Y, "Two mitofusin proteins, mammalian homologues of FZO, with distinct functions are both required for mitochondrial fusion", J Biochem (Tokyo), 134, pp.333~344 (2003)
28. Verhoeven K, "Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy", Am J Hum Genet, 72, pp.722~727 (2003)
29. Jordens I, "The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors", Curr Biol, 11, pp.1680~1685 (2001)
30. Klein CJ, "The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders", Neurology, 60, pp.1151~1156 (2003)
31. Klein CJ, "TRPV4 mutations and cytotoxic hypercalcemia in axonal Charcot-Marie-Tooth neuropathies", Neurology, 76, pp.887~894 (2011)
32. Antonellis A, "Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V", Am J Hum Genet, 72, pp.1293~1299 (2003)
33. Carter J, "Neurofilament (NF) assembly; divergent characteristics of human and rodent NF-L subunits", J Biol Chem, 273, pp.5101~5108 (1998)
34. Brownlees J, "Charcot- Marie-Tooth disease neurofilament mutations disrupt neurofilament assembly and axonal transport", Hum Mol Genet, 11, pp.2837~2844 (2002)
35. Fabrizi GM, "Giant axon and neurofilament accumulation in Chartcot-Marie-Tooth disease type 2E", Neurology, 62, pp.1429~1431 (2004)
36. Irobi J, "Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy", Nat Genet, 36, pp.597~601 (2004)
37. Benndorf R, "Shocking degeneration", Nat Genet, 36, pp.547~548 (2004)
38. Hahn AF, "Genotype", phenotype correlations in X-linked dominant Charcot-Marie- Tooth disease, 1999, pp.883, 366~382
39. Scherer SS, "Molecular specializations at nodes and paranodes in peripheral nerve", Microsc Res Tech, 34, pp.452~461 (1996)
40. 최병옥, "Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients.", Human mutation, 24(2), pp.185~186, John Wiley & Sons Inc.
41. Scherer SS, "Connexin32 is a myelin-related protein in the PNS and CNS", J Neurosci, 15, pp.8281~8294 (1995)
42. Dubourg O, "Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease", Brain, 124, pp.1958~1967 (2001)
43. Rozear MP, "Hereditary motor and sensory neuropathy, X-linked a half century follow-up", Neurology, 37, pp.1460~1465 (1987)
44. Hahn AF, "X-linked dominant hereditary motor and sensory neuropathy", Brain, 113, pp.1511~1525 (1990)
45. Baxter RV, "Ganglioside- induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A", 8q21, 2002, pp.30, 21~22
46. Liu H, "Isolation of 10 differentially expressed cDNAs in differentiated Neuro2a cells induced through controlled expression of the GD3 synthase gene", J Neurochem, 72, pp.1781~1790 (1999)
47. Cuesta A, "The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease", Nat Genet, 30, pp.22~25 (2002)
48. Bolino A, "Charcot-Marie- Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2", Nat Genet, 25, pp.17~19 (2000)
49. Gambardella A, "Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths (CMT4B)", Ann NY Acad Sci, 883, pp.47~55 (1999)
50. Senderek J, "Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2", 11p15, 2003, pp.12, 349~356
51. Senderek J, "Mutations in a gene encoding a novel SH3", TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy, 2003, pp.73, 1106~1119
52. Hunter M, "Mutation screening of the N-myc downstream-regulated gene 1 (NDRG1) in patients with Charcot-Marie-Tooth Disease", Hum Mutat, 22, pp.129~135 (2003)
53. Guilbot A, "A mutation in Periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease", Hum Mol Genet, 10, pp.415~421 (2001)
54. Gillespie CS, "Periaxin, a novel protein of myelinating Schwann cells with a possible role in axonal ensheathment", Neuron, 12, pp.497~508 (1994)
55. Kim Y, "X-linked dominant Charcot-Marie-Tooth disease with connexin 32 (Cx32) mutations in Koreans", CLINICAL GENETICS, 81(2), pp.142~149 (2012), WILEY-BLACKWELL[DOI]
56. Sereda M, "A transgenic rat model of Charcot-Marie-Tooth disease", Neuron, 16, pp.1049~1060 (1996)
57. Perea J, "Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A", Hum Mol Genet, 10, pp.1007~1018 (2001)
58. Desarnaud F, "Progesterone stimulates the activity of the promoters of peripheral myelin protein-22 and protein zero genes in Schwann cells", J Neurochem, 71, pp.1765~1768 (1998)
59. Eldridge CF, "Differentiation of axon-related Schwann cells in vitro. I. Ascorbic acid regulates basal lamina assembly and myelin formation", J Cell Biol, 105, pp.1023~1034 (1987)
60. Rodriguez Melendez R, "Importance of water-soluble vitamins as regulatory factors of genetic expression", Rev Invest Clin, 54, pp.77~83 (2002)
61. Fu SY, "The cellular and molecular basis of peripheral nerve regeneration", Mol Neurobiol, 14, pp.67~116 (1997)
62. Sahenk Z, "Effects of PMP22 duplication and deletions on the axonal cytoskeleton", Ann Neurol, 45, pp.16~24 (1999)
63. d’Ydewalle C, "HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease", Nat Med, 24(17), pp.968~974 (2011)[DOI]
64. Thomson JA, "Embryonic stem cell lines derived from human blastocysts", Science, 282, pp.1145~1147 (1998)
65. Takahashi K, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors", Cell, 126, pp.663~676 (2006)
66. Takahashi K, "Induction of pluripotent stem cells from adult human fibroblasts by defined factors", Cell, 131, pp.861~872 (2007)
67. Wernig M, "Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson’s disease", Proc Natl Acad Sci U S A, 105, pp.5856~5861 (2008)
68. Ebert AD, "Induced pluripotent stem cells from a spinal muscular atrophy patient", Nature, 457, pp.277~280 (2009)
69. Lee G, "Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs", Nature, 461, pp.402~406 (2009)
70. Carvajal-Vergara X, "Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome", Nature, 465, pp.808~812 (2010)

관련 논문AI추천